The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Seattle Genetics Inc

Nasdaq: SGEN
Last

(U.S.) $62.73

Today's change-0.34 -0.54%
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.
 

Seattle Genetics Inc

Nasdaq: SGEN
Last

(U.S.) $62.73

Today's change-0.34 -0.54%
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.

Seattle Genetics Inc down (U.S.)$0.34

Seattle Genetics Inc closed lower Friday, dropping (U.S.)$0.34 or 0.54% to (U.S.)$62.73. Shares have lost 4.23% over the last five days, but have gained 18.87% over the last year to date. This security has outperformed the S&P 500 by 87.27% during the last year.

Key company metrics

  • Open(U.S.) $63.14
  • Previous close(U.S.) $63.07
  • High(U.S.) $63.22
  • Low(U.S.) $61.50
  • Bid / Ask(U.S.) $60.00 / (U.S.) $66.88
  • YTD % change+18.87%
  • Volume805,273
  • Average volume (10-day)1,033,490
  • Average volume (1-month)843,140
  • Average volume (3-month)1,217,703
  • 52-week range(U.S.) $28.32 to (U.S.) $75.36
  • Beta2.30
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.99
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-33.51%

Although this company's net profit margin is negative, it is above the industry average and implies that Seattle Genetics Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX1.57%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue10510695111
Total other revenue--------
Total revenue10510695111
Gross profit949585102
Total cost of revenue12111010
Total operating expense161139129132
Selling / general / administrative41353330
Research & development108938693
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-56-32-33-21
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-55-32-33-20
Income after tax-55-32-33-20
Income tax, total--------
Net income-55-32-33-20
Total adjustments to net income--------
Net income before extra. items-55-32-33-20
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-55-32-33-20
Inc. avail. to common incl. extra. items-55-32-33-20
Diluted net income-55-32-33-20
Dilution adjustment--------
Diluted weighted average shares142141140140
Diluted EPS excluding extraordinary itemsvalue per share-0.39-0.23-0.23-0.15
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.39-0.23-0.23-0.15